The history of copyright's flagship drug presents a nuanced case for investors in the medicinal sector. While initially a phenomenal success, producing vast sums, the exclusivity end and the subsequent flood of off-brand versions have drastically impacted income. This poses questions about the future profitability of related medication check here d